OCT-Angiography and Adaptive Optics in Patients With Memory Impairment

Launched by FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD · May 14, 2020

Keywords

ClinConnect Summary

This clinical trial is exploring how certain eye imaging techniques can help us understand memory problems related to conditions like Alzheimer's disease, Lewy Body disease, and Parkinson's disease with dementia. Researchers believe that looking at the retina, which is the light-sensitive layer at the back of the eye, can reveal important information about these neurocognitive disorders (NCD). By using two special imaging methods—Optical Coherence Tomography Angiography (OCT-A) and Adaptive Optics (AO)—the study aims to see if there are different patterns in the eye’s blood vessels and structure between people with memory issues and those without.

To participate in this study, you or someone you know should be experiencing memory complaints or be a caregiver for someone with such complaints. However, there are certain criteria that could exclude someone from participating, such as being pregnant, having specific eye or neurological conditions, or certain medical histories. If eligible, participants will undergo non-invasive eye imaging to help researchers better understand how memory problems are linked to changes in the retina. This trial is currently recruiting participants aged 65 and older, and it offers a unique opportunity to contribute to important research in this field.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient presenting in memory consultation for memory complaint or person accompanying a patient in memory consultation for memory complaint
• Exclusion Criteria:
• • pregnant or lactating women
• • history of known non-degenerative neurological pathology (tumor, stroke territorial, in particular multiple sclerosis)
• • history of retinal pathology
• • ametropia greater in absolute value than 3 diopters on the sphere, or/and 1.5 diopters on the cylinder.
• • history of taking ethambutol for more than 2 months
• • history of takingsynthetic antimalarial for more than 2 years
• • Mini Mental State Score (MMS) and / or Montreal Cognitive Assessment (MoCA) \<10 for patients and 26 for accompanying persons
• • MRI contraindication (for patients only)